Scarica l'app Stockscreener
14.47
0.28%
0.04
Precedente Chiudi:
$14.43
Aprire:
$15.64
Volume 24 ore:
291.65K
Relative Volume:
1.52
Capitalizzazione di mercato:
$315.06M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+4.70%
1M Prestazione:
+45.87%
6M Prestazione:
+34.73%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$14.43
$15.75
Intervallo di 1 settimana:
$12.54
$16.00
Portata 52W:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Nome
Aardvark Therapeutics Inc
Settore
Industria
Telefono
(858) 225-7696
Indirizzo
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Confronta AARD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
14.47 | 314.19M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Iniziato | William Blair | Outperform |
| 2025-12-03 | Iniziato | Raymond James | Strong Buy |
| 2025-11-07 | Iniziato | BTIG Research | Buy |
| 2025-09-29 | Iniziato | Stifel | Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Iniziato | BofA Securities | Buy |
| 2025-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Iniziato | Morgan Stanley | Overweight |
| 2025-03-10 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aardvark Therapeutics Inc Borsa (AARD) Ultime notizie
Insider Buying: Aardvark Therapeutics CEO, Secretary & Director Bought US$101k Of Shares - simplywall.st
HC Wainwright Has Negative Outlook for AARD FY2025 Earnings - Defense World
Aardvark Therapeutics (NASDAQ:AARD) CEO Tien-Li Lee Purchases 7,000 Shares - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) CFO Purchases $43,200.00 in Stock - MarketBeat
Insider Stock Purchases: December 13, 2025 - Quiver Quantitative
William Blair initiates coverage on Aardvark Therapeutics stock with Outperform rating - Investing.com Canada
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 By Investing.com - Investing.com Nigeria
Insider Buying: Nelson Sun Acquires Additional Shares of Aardvar - GuruFocus
Lee Tien-Li, CEO of Aardvark, buys $101k in AARD stock - Investing.com Australia
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 - Investing.com
William Blair Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst - Benzinga
William Blair Initiates Aardvark Therapeutics With Outperform Rating - marketscreener.com
Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market Potential - TipRanks
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy By Investing.com - Investing.com South Africa
Aardvark Therapeutics’ Promising Progress and Market Potential: Analyst Recommends Buy - TipRanks
Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy - Investing.com Canada
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com Nigeria
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target By Investing.com - Investing.com South Africa
Aardvark doses first Australian patient in phase 3 PWS hunger trial - Investing.com Nigeria
Aardvark doses first Australian patient in phase 3 PWS hunger trial By Investing.com - Investing.com South Africa
Aardvark Therapeutics Begins Phase 3 HERO Trial Dosing - TipRanks
Aardvark Therapeutics Doses First Patient in HERO Phase 3 Trial - TradingView — Track All Markets
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome - The Manila Times
Aardvark Therapeutics (Nasdaq: AARD) expands HERO PWS trial, targets Q3 2026 data - Stock Titan
Aardvark Therapeutics begins phase 3 HERO trial dosing - MSN
Retail Investors in Aardvark Therapeutics, Inc. (NASDAQ:AARD) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 28% Last Week - 富途牛牛
Will Aardvark Therapeutics Inc. stock benefit from commodity pricesMarket Growth Report & Daily Market Momentum Tracking - Newser
Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation - MSN
Raymond James Financial Begins Coverage on Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat
Individual investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest shareholders, saw gain in holdings value after stock jumped 23% last week - simplywall.st
Aardvark Therapeutics initiated with a Strong Buy at Raymond James - MSN
AARD: Phase 3 Prader-Willi data expected Q3 2026; obesity program readout by end of next year - TradingView
Aardvark Therapeutics (AARD) Stock Analysis Report | Financials & Insights - Benzinga
Raymond James Initiates Aardvark Therapeutics at Strong Buy - marketscreener.com
Raymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy - Investing.com UK
AARDAardvark Therapeutics Inc Dividends - Finviz
Aardvark Therapeutics Reports Q3 2025 Financial Results - MSN
Aardvark Therapeutics Hosts Investor Webinar on Drug Programs - MSN
Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) PT at $30.63 - Defense World
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What risks investors should watch in Aardvark Therapeutics Inc. stockEarnings Trend Report & Real-Time Chart Breakout Alerts - BỘ NỘI VỤ
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December - The Manila Times
What is the current Price Target and Forecast for Aardvark Therapeutics, Inc. (AARD) - Zacks Investment Research
Aardvark Therapeutics Inc Azioni (AARD) Dati Finanziari
Non sono disponibili dati finanziari per Aardvark Therapeutics Inc (AARD). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Aardvark Therapeutics Inc Azioni (AARD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Dec 11 '25 |
Buy |
14.48 |
7,000 |
101,395 |
1,551,613 |
| Lee Tien-Li | Chief Executive Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,229 |
5,211 |
1,544,613 |
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):